How is Zhu Xuan Biology doing in the research of macromolecular and micromolecule drugs?

Zhu Xuan's biological innovation has been developed for nearly ten years, and it has two R&D systems: small molecule chemicals and macromolecular biopharmaceuticals. Now it has formed a complete R&D system and a scientific research team with independent innovation and R&D capability. The company's products cover small molecules, monoclonal antibodies, bispecific antibodies, antibody-coupled drugs, fusion proteins and other types. The layout of long, medium and short pipelines is perfect and balanced, with the ability of continuous innovation and continuous output: it is expected that 2-3 varieties will be listed next year, and profits will be realized in 3 years, which will provide a good boost for the sustainable development of innovative products from the source.